Westhampton Capital LLC Sells 200 Shares of Abbott Laboratories (NYSE:ABT)

Westhampton Capital LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 3.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,700 shares of the healthcare product maker’s stock after selling 200 shares during the period. Westhampton Capital LLC’s holdings in Abbott Laboratories were worth $645,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Baron Wealth Management LLC lifted its holdings in Abbott Laboratories by 72.4% during the fourth quarter. Baron Wealth Management LLC now owns 3,544 shares of the healthcare product maker’s stock worth $401,000 after buying an additional 1,488 shares during the period. Gries Financial LLC raised its position in shares of Abbott Laboratories by 6.7% in the 4th quarter. Gries Financial LLC now owns 15,513 shares of the healthcare product maker’s stock worth $1,755,000 after acquiring an additional 971 shares in the last quarter. Hanson & Doremus Investment Management lifted its stake in shares of Abbott Laboratories by 15.3% during the 4th quarter. Hanson & Doremus Investment Management now owns 12,876 shares of the healthcare product maker’s stock worth $1,456,000 after purchasing an additional 1,711 shares during the last quarter. Foster & Motley Inc. grew its stake in Abbott Laboratories by 17.7% in the fourth quarter. Foster & Motley Inc. now owns 5,309 shares of the healthcare product maker’s stock valued at $600,000 after purchasing an additional 800 shares during the last quarter. Finally, Invesco LLC boosted its holdings in shares of Abbott Laboratories by 13.4% in the 4th quarter. Invesco LLC now owns 10,500 shares of the healthcare product maker’s stock valued at $1,188,000 after buying an additional 1,244 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ABT shares. Piper Sandler increased their target price on shares of Abbott Laboratories from $131.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, October 17th. Barclays reissued an “overweight” rating and issued a $158.00 price objective (up previously from $149.00) on shares of Abbott Laboratories in a research report on Monday. UBS Group upped their target price on Abbott Laboratories from $146.00 to $148.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Sanford C. Bernstein raised their price target on Abbott Laboratories from $133.00 to $138.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, Morgan Stanley upped their price objective on shares of Abbott Laboratories from $107.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.06.

Abbott Laboratories Trading Up 0.4 %

NYSE ABT opened at $127.86 on Thursday. The company has a fifty day moving average of $115.71 and a 200 day moving average of $113.80. The company has a market capitalization of $221.77 billion, a PE ratio of 16.71, a P/E/G ratio of 2.51 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $129.85.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting analysts’ consensus estimates of $1.34. The firm had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $11.03 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The company’s revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.19 earnings per share. Research analysts forecast that Abbott Laboratories will post 5.15 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be paid a $0.59 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 annualized dividend and a dividend yield of 1.85%. The ex-dividend date of this dividend is Wednesday, January 15th. Abbott Laboratories’s payout ratio is currently 30.85%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.